We report 41 consecutive chronic lymphocytic leukemia (CLL) patients who underwent allogeneic hematopoietic cell transplantation (HCT) following fludarabine, melphalan and alemtuzumab conditioning. Donors were 24 HLA-matched siblings and 17 unrelated volunteers, 4 of them mismatched with their donors. All but 3 patients had initial hematological recovery, but 5 more patients had secondary graft failure. Median intervals to neutrophil (> 0.5 × 10 9 /l) and platelet (> 20 × 10 9 /l) recovery were 14 (range 9-30) and 11 (range 8-45) days, respectively. Eleven patients (27%) relapsed and received escalated donor lymphocyte infusions, but only 3 of them had a sustained response. Acute and chronic graft-versus-host disease (GVHD) was observed in 17 (41%) and 13 (33%) patients, respectively.
INTRODUCTION
The course of chronic lymphocytic leukemia (CLL) is extremely variable. While some patients have an indolent disease without any need for therapeutic interventions, others succumb rapidly despite intensive treatment.
1 About a third of CLL patients are younger than 60 years and 10-15% are younger than 50
years. In young adults, CLL has no major distinctive features, the prognostic factors are the same as those in older patients, and patients with advanced disease have a median survival of 24-72 months with conventional chemotherapy. [2] [3] [4] In particular, CLL patients who have failed to respond to fludarabine or any other purine analog have the poorest prognosis, with a median survival of approximately 8 months and 1-year survival around 40%. 5 Autologous hematopoietic cell transplantation (HCT) is feasible in young patients with CLL and results in long-lasting clinical and molecular remissions. 6 The transplantrelated mortality (TRM) is less than 10%, with complete response rates around 80%, and a risk-matched case-control study revealed a prolongation of survival compared to conventional therapy. 7 However, these results have never been confirmed in prospective randomized studies, and it is also becoming evident that most patients attaining complete remissions after an autograft will eventually relapse. 8 Prolonged remissions have been achieved with conventional allogeneic HCT. 9 Unfortunately, this procedure is only suitable in a small proportion of young patients with a compatible donor and is hampered by a TRM of about 50%. 10 After early attrition due to TRM, the survival curves approach a plateau and the achievement of a molecular remission is more likely than after autologous transplant, probably reflecting a graft-versus-leukemia effect. 11 In an effort to reduce the TRM, several reducedintensity conditioning regimens have been developed. The UK Collaborative Group's protocol incorporates anti-CD52 monoclonal antibody (alemtuzumab; Campath-1H) in order to deplete recipient and incoming donor T cells, providing durable engraftment while significantly reducing the risk of graftversus-host disease (GVHD) in both the HLA-matched sibling and unrelated donor setting. 12, 13 Furthermore, CD52 is also expressed at high density in CLL cells. Indeed, alemtuzumab has proven activity in patients with advanced CLL, even if refractory to fludarabine. 14, 15 Unfortunately, the use of alemtuzumab also delays post-HCT immune reconstitution, increasing the risk of infective complications and potentially impairing the graft-versus-leukemia effect. This reduced anti-tumor activity may require the early administration of sequential donor lymphocyte infusions (DLI) after transplant. [16] [17] [18] Based on the encouraging results obtained with an alemtuzumab-based reduced intensity regimen in lowgrade non-Hodgkin's 19, 20 and Hodgkin's lymphoma, 21 the aim of this study was to evaluate the feasibility and efficacy of the same regimen in patients with advanced CLL.
PATIENTS AND METHODS

Study patients
The study protocol was approved by all participant centers' ethics committees and all patients and donors gave written informed consent. We prospectively collected data from 41 consecutive patients with advanced CLL who underwent allogeneic HCT using a fludarabine-melphalan-alemtuzumab conditioning
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Patients were excluded if older than 70 years, the left ventricular ejection fraction was less than 40%, creatinine clearance was less than 30 ml/min/1.73 m 2 , serum bilirubin was greater than 34 µM or liver transaminases were more than 3 times the upper limit. Two patients who experienced a high grade (Richter's) transformation before the transplant were included in the study.
Conditioning regimen, GVHD prophylaxis and stem cell source
The conditioning regimen consisted of alemtuzumab 20 mg/d from day -8 to -4 (total dose 100 mg), Fourteen patients (34%) received a total dose of 60 mg (6 patients), 50 mg (7) and 40 mg (1) of alemtuzumab on days -2 and -1 as part of an ongoing de-escalation trial. Cyclosporine was administered as an intravenous infusion over 1 hour at 3 mg/kg/d starting on day -1, with a target level of 150-200 ng/ml. In the absence of GVHD, cyclosporine was tapered from 3 months following transplantation.
Acute and chronic GVHD were graded according to standard criteria. 23 On day 0, patients received 
Analysis of donor chimerism and donor lymphocyte infusions
Whole blood and lineage-specific chimerism (in T-cell and myeloid lineages) was assessed by means of 
Definitions and statistical analysis
Disease response was assessed using National Cancer Institute Working Group (NCI-WG) criteria. 24 Briefly, complete remission (CR) was defined as absence of lymphadenopathy, hepatosplenomegaly and constitutional symptoms, less than 30% lymphocytes in the bone marrow and a normal full blood count.
Partial remission (PR) was defined as 50% reduction in peripheral blood lymphocyte count, lymphadenopathy and hepatosplenomegaly with a normal full blood count (or 50% improvement over baseline). Where possible, patients in CR had multi-parameter flow cytometry analysis and PCR for immunoglobulin heavy-chain rearrangement performed on bone marrow and/or peripheral blood samples every 3-6 months post transplant.
Patients who achieved a significant response (CR or PR by NCI-WG criteria 24 ) to the last chemotherapy regimen before transplantation were considered to have chemo-sensitive disease. Conversely, patients failing to respond to the last chemotherapy regimen before transplantation were considered to have chemo-refractory disease. Fludarabine refractoriness was defined as failure to achieve PR or CR to the last fludarabine-based regimen administered.
Time-to-event outcomes with competing risks (i.e., TRM and relapse rate) were estimated by cumulativeincidence curves. Comparison of cumulative-incidence curves was performed by Lunn-McNeill's approach in which Cox regression is applied to competing risks. Overall survival (OS) and progressionfree survival (PFS) were estimated by the Kaplan-Meier method and compared using the log-rank test.
Several factors were analyzed for their association with OS, PFS and TRM, including age ( 55 vs > 55 years), donor type (sibling vs unrelated), status at transplant (PD vs CR + PR), prior autologous transplant, prior fludarabine, alemtuzumab or rituximab therapy, number of prior chemotherapy regimens (< 3 vs 3), alemtuzumab dose in the conditioning regimen (< 100 vs 100 mg) and fludarabine refractoriness. We also evaluated the so-called "center effect" by splitting the patients in two groups:
those treated at centers who contributed 8 or more patients and those treated at centers who contributed less than 8 patients. Subsequently, multivariate analysis according to the Cox proportional hazards regression model was used to explore the independent effect of variables that showed a significant influence on OS or PFS by univariate analysis. In all statistical calculations, a P value <0.05 was considered significant.
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RESULTS
Patient characteristics
Age at transplant ranged from 37 to 67 years (median 54 years). At the time of transplant, 7 patients (17%) had chemo-refractory and 34 (83%) chemo-sensitive disease (Table 1) . Eleven patients (31%) were refractory to fludarabine at the time of transplant and 3 others (8%) had it stopped due to autoimmune hemolytic anemia (AIHA, 2 cases) and immune thrombocytopenic purpura (ITP, 1 case). Two further patients had fludarabine-independent immune cytopenias pre-HCT (1 AIHA, 1 ITP). Pre-transplant characteristics of fludarabine refractory patients are shown in Table 2 .
Eleven patients (27%) received their allografts having failed an autologous transplantation. These patients had a similar age (median 55, range 40-66 years) and number of prior chemotherapy regimens (median 4, range 2-5 regimens) as the whole cohort. Three out of these 11 patients (27%) had chemo-refractory disease at the time of transplant, and 8 of them (73%) received their graft from an unrelated donor.
Engraftment and donor chimerism
The median number of CD34+ cells infused was 5. 
achieved full donor chimerism and 3 of them eventually relapsed, but they all remain alive with stable disease (Table 3) .
Graft-versus-host disease
Acute GVHD (aGVHD) was observed in 17 patients (41%), but only 4 patients (10%) developed grade III-IV aGVHD. Twelve patients (29%) developed aGVHD after transplantation and 5 further patients (12%) following DLI. No statistical difference was observed between unrelated and sibling donor recipients (29% vs 29%, P = 1.0, Fisher's exact test).
Thirty-nine patients (95%) survived at least until day +100 and were assessable for chronic GVHD (cGVHD). The incidence of cGVHD was also low, with a total of 13 patients (33%) developing limited (n = 11) and extensive (n = 2) cGVHD following transplant or DLI. There was a trend towards a higher incidence of cGVHD in unrelated compared to sibling donor recipients (53% vs 21%, P = 0.079, Fisher's exact test).
Two patients with grade III and IV aGVHD and both patients with extensive cGVHD died of infections, 2 of them of pulmonary aspergillosis, resulting in a GVHD-related mortality of 10%.
Infections
Infections were the most common cause of death and morbidity in our cohort of patients. Nine patients Six out of 7 patients (86%) transplanted with chemo-refractory disease achieved a complete or partial response, which was sustained in 3 of them (43%). One patient did not respond to the procedure and died, 1 patient died of a fungal cerebral abscess, and 2 patients relapsed shortly after transplantation. Both
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For patients with chemo-sensitive disease, the overall response rate (ORR = CR + PR) was 100%, with only 3 of these patients remaining in PR due to persistent cytopenias post-HCT. Nine patients (28%) relapsed at a median of 5 months post-HCT (range 2.1 -39.4 months). All relapsed patients received DLI, but these were effective in only 3 of them (33%). Interestingly, 4 out of 6 patients who did not respond to DLI are currently alive and well and only 2 have died of progressive disease. In three of these 6 unresponsive patients, disease relapse was heralded by mixed chimerism (see above) and, even though DLI were commenced at that stage, full donor chimerism was never achieved and relapse could not be avoided ( Table 3 ).
The probabilities of day 100 and 2-year TRM were 5% (1%-19%) and 26% (14%-46%), respectively, and the 2-year relapse risk was 29% (17%-49%) (Figure 1) . Age was the only factor with a significant impact on the TRM (hazard ratio 3.52 [95% CI: 1.06-11.77]; P = 0.041). Other pre-transplant factors such as prior autologous transplant; prior therapy with fludarabine, alemtuzumab or rituximab; number of prior chemotherapy regimens (< 3 vs 3), alemtuzumab dose in the conditioning regimen (< 100 vs 100 mg), or fludarabine refractoriness had no significant effect on the TRM.
Kaplan-Meier estimates of OS and PFS are also shown in Figure 1 . Estimated OS and PFS at 2 years were 51% (95% IC: 33%-69%) and 45% (27%-62%), respectively. Importantly, donor type (sibling vs unrelated) did not have a significant impact on survival.
Three factors turned out to have a significant effect on OS by univariate analysis: older age (P = 0.0381), fludarabine refractoriness (P = 0.0437), and center-effect (P = 0.0131) but none of these variables remained significant in a multivariate regression analysis. Older age (P = 0.0176), center-effect (P = 0.0044) and fludarabine refractoriness (P = 0.0015) also had a significant impact on PFS by univariate However, this center-effect is difficult to gauge because both groups were unbalanced in terms of prior chemotherapy and type of donor. Indeed, 90% of patients transplanted in the "less experienced" centers had 3 or more prior chemotherapy lines compared with 52% of patients transplanted in the "more experienced" centers (P = 0.016, Fisher's exact test). Also, 63% of patients in the first group received an unrelated allograft compared with 23% of patients in the latter group (P = 0.012, Fisher's exact test).
DISCUSSION
Modern salvage therapies, including alemtuzumab and/or rituximab, are promising in young patients with advanced CLL, 15, 25 but it is uncertain whether they will lead to a prolonged survival. Over the last few years, more data has become available with regard to reduced intensity allogeneic transplant in CLL. [26] [27] [28] [29] The aim of these studies is to deliver the advantages of the graft-versus-leukemia effect but without the TRM associated with conventional HCT.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From A reduced intensity protocol comprising fludarabine and cyclophosphamide ± rituximab was used in 17 patients with HLA-identical sibling donors at the MD Anderson Cancer Center. 26 The incidence of cGVHD was 60%, with 5 patients dying of cGVHD or GVHD-related infections. The 2-year TRM was 22% but the response rate was high (94%), even though the effect of post-transplant rituximab is impossible to evaluate. The estimated 2-year OS and PFS were 80 and 60%, respectively, with no clear evidence of a plateau. 20 The Cooperative German Transplant Study Group reported on the outcome of 30 patients conditioned with fludarabine, busulfan and ATG. 27 Fifteen had sibling and 15 had unrelated donors. TRM was 15% at 2 years and aGVHD was relatively common despite in vivo T-cell depletion, particularly in those patients with unrelated donors. The incidence of cGVHD was 75%, and 40% attained a CR following HCT. Only a minority of patients was eligible for DLI because of the high GVHD rates.
Only 1 out of 6 patients had a durable response to DLI. The 2-year OS and PFS were 72% and 67%
respectively. The Seattle group has very recently reported their experience with low dose total body irradiation ± fludarabine in 64 CLL patients. 28 The 2-year TRM was 22%, and 50% of patients developed extensive cGVHD. Responses were observed in 67% of patients with measurable disease pre-HCT. The 2-year relapse rate, OS and PFS were 26%, 60% and 52%, respectively. Unrelated donor HCT induced lower relapse rates than sibling HCT, which suggests a powerful graft-vs-leukemia effect. However, patients who experienced disease progression generally did not respond to DLI, with only 1 PR documented out of 6 patients treated (17% response rate). Finally, 77 CLL patients were identified in a recent EBMT survey. 29 Unfortunately, the interpretation is complicated by the diversity of conditioning regimens. The 1-year TRM was 18%, and the 2-year EFS and OS were 56% and 72% respectively. The 2-year probability of progression or relapse was 31%. Achievement of CR (in 69% of patients) was significantly associated with cGVHD. Furthermore, objective responses were obtained in four of 12 patients (33%) who received DLI for insufficient disease control.
Our alemtuzumab-based regimen was feasible and effectively reduced the incidence of GVHD in both sibling and unrelated donor recipients compared to other published regimens. Indeed, the overall incidence of aGVHD was 41% (12% post-DLI), with an incidence of grade III-IV GVHD of only 10%.
The cGVHD rate was also low (33%) and only 2 patients developed extensive cGVHD, both following DLI. GVHD-related mortality was only 10%, which compares very favorably with all previous reports.
Trilineage engraftment was achieved in all but 1 patient. Unfortunately, 5 further patients rejected their grafts at a median of 4 months post-HCT. Four of these patients received a second stem cell infusion, which was conditioned with ATG in 2 of them as per institutional protocol. All 4 patients engrafted and none developed GVHD, but both patients receiving ATG died shortly afterwards of EBV-induced post transplant lymphoproliferative disease (PTLD) and RSV pneumonia, respectively. ATG has been frequently used in this setting to enhance engraftment and prevent GVHD, 30 but it may have been unnecessary in this subgroup of CLL patients previously conditioned with alemtuzumab. Indeed, the risk of PTLD depends greatly on the method of T-cell depletion, being considerably higher when specific Tcell antibodies (ATG) rather than T-and B-cell antibodies (alemtuzumab) are used. 31 Furthermore, the anti-tumor activity of the conditioning regimen was impressive, with 100% chemosensitive and 86% of chemo-refractory patients initially attaining a CR or PR post-HCT. This is not surprising as alkylating agents, purine analogs and monoclonal antibodies constitute the mainstay of
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From treatment for advanced stage CLL. Four patients had active immune cytopenias at the time of transplant, two of them induced by fludarabine therapy, but this was not an impediment, nor did the cytopenias worsen following HCT. Unfortunately, these responses were durable in only 74% and 43% of chemosensitive and chemo-refractory patients, respectively. The 2-year relapse risk was 29%, with no difference between sibling and unrelated donors. Furthermore, DLI was effective when used for reversing mixed chimerism, but not for relapsed/progressive disease. Our study revealed that only 3 out of 11 patients (27%) who received DLI for relapsed/progressive disease actually responded to the procedure (Table 3 ).
This observation mirrors the results obtained by 3 different groups, where DLI only achieved an ORR of 14-17% in CLL patients with relapsed/progressive disease post-HCT. 16, 27, 28 The MD Anderson group, on the other hand, has reported a very good response rate to DLI in a subset of 7 patients with progressive disease (ORR 86%), but interpretation of this report is complicated by the fact that rituximab was concomitantly administered in 5 patients. The 2-year TRM was significantly higher compared to our previous report on reduced-intensity transplantation in patients with low grade lymphoma (26% vs 11%). 19 This was mainly due to a high incidence of severe bacterial, viral and fungal infections. Unlike patients with follicular lymphoma, who usually die of refractory disease or transformation to high-grade disease, 33 it is widely acknowledged that infections account for up to 50% of all CLL-related deaths. 34 This susceptibility is both disease and therapy-related, 35 and is secondary to multiple factors including hypogammaglobulinemia, defective Tand NK-cell function, neutropenia and deficient complement activity. Furthermore, alemtuzumab depletes incoming T-cells and therefore delays the immune reconstitution post-HCT. Indeed, the median time to CD4 + T-cell recovery (> 0.2 x 10 9 /l) with this protocol is 9 months, which is much more delayed than with other myeloablative or nonmyeloablative regimens. 17, 36 In this study, CMV reactivation was a very common event (68%), although only 2 patients developed CMV disease despite pre-emptive treatment. 36 Other particularly problematic viruses were adenovirus, EBV and RSV, all having a significant impact on our patients' morbidity and mortality. 37, 38 We also observed other opportunistic infections, including 2 cases of fatal pulmonary aspergillosis and 1 case of cerebral nocardiosis, in 3 patients receiving corticosteroids due to cGVHD, highlighting the importance of appropriate anti-infective prophylaxis in this setting.
Unexpectedly, the graft failure rate (15%) was significantly higher than previously reported for patients with Hodgkin's and non-Hodgkin's lymphoma conditioned with the same regimen. 19, 21 The limited number of patients in our study prevents us from reaching any definitive conclusion, but we speculate this is disease related. In particular, the deficient complement activity described in CLL patients might have
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From reduced the cytotoxic effect of alemtuzumab, leaving residual host T-cells capable of rejecting the graft. 39 Furthermore, there is some evidence that sustained allogeneic engraftment is facilitated by host dendritic cells and other ancillary marrow elements, 40 which are severely defective in CLL patients. 41 Interestingly, a recent study on unrelated transplantation for CLL using myeloablative conditioning regimens revealed a very similar incidence of graft failure (18%). 42 Fludarabine refractoriness emerged as a clear prognostic factor in this group of transplant patients and had a significant impact of both OS and PFS. Indeed, fludarabine refractory patients had a 1-year and 2-year survival of 54% (24-84%) and 31% (1%-61%), respectively, which is only marginally better than the results obtained with chemotherapy alone. 5 Alternative therapies and/or transplantation schemes might be necessary in this group of poor-prognosis patients. We also observed a possible center effect, but this is difficult to assess due to unbalanced pre-transplant characteristics.
In summary, our alemtuzumab-based reduced intensity protocol is feasible and effective in patients with poor-risk CLL with a very impressive response rate and a relatively low GVHD rate. However, TRM remains relatively high as a result of a variety of viral and fungal infections. Ongoing studies are trying to address the efficacy of reduced doses of alemtuzumab in this group of very immunosupressed patients. 
